🇺🇸 FDA
Patent

US 11479556

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

granted A61PA61P35/00A61P37/00

Quick answer

US patent 11479556 (Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway) held by NURIX THERAPEUTICS, INC. expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NURIX THERAPEUTICS, INC.
Grant date
Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
106
CPC classes
A61P, A61P35/00, A61P37/00